ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR Mohamad Mohty Hôpital Saint-Antoine AP-HP @sorbonne_univ_ #oncology onclive.com/view/ares-tria…

For all of those who are taking the #Patients angle when participating to the advent of the #Microbiome field, do check this excellent 12 mins video from Jason Gale featuring MaaT Pharma youtube.com/watch?v=P8pd0T…

📰 - MaaT Pharma in Bloomberg Bloomberg - We’re proud to see our work featured in Bloomberg, spotlighting the potential of microbiome therapy in cancer care. The article and film share the inspiring patient’s story, who overcame aGvHD, a life-threatening complication after a

🎥 Behind the scenes in San Francisco! MaaT Pharma’s CEO, @Herve Affagard Herve Affagard sat down today with FierceBiotech 's Rebecca Willumson Rebecca Willumson during #JPM2025 for an exclusive interview. They discussed our exciting Phase 3 ARES data announcement and what’s ahead

Steep streets of #SanFrancisco are like the entrepreneur's journey: full of uphill climbs, unexpected turns, and rewarding views at the top. No exception during #JPM2025, every climb leads to a breathtaking view. 🚋✨ #Entrepreneurship #GoodVibes MaaT Pharma

.MaaT Pharma 's MaaT013 has the potential to be the first approved third-line treatment option & transform the survival outcomes and redefine long-term prospects for approximately 3,000 third-line GI-aGvHD patients per year in the U.S., Canada & Europe. bit.ly/3Wd57jk

📄[Press release] – MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT🩸 maatpharma.com/january-21-202… #Microbiome #BloodCancer #Cancer #DSMB #Safety #Tolerability #Phase2

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif du deuxième DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 👉maatpharma.com/fr/21-janvier-… #Microbiote #CancersDuSang #Cancer #DSMB #Sécurité #Tolérabilité

💡 [#WorldCancerDay 2025] - There’s never been a more exciting time in #microbiome #research, especially in #oncology. We’re proud that our ARES trial is contributing to the field, and to a potential breakthrough treatment. Learn more from Professor Mohamad Mohty on what it could

📄 [Press release] – MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ The independent DSMB has recommended that the study proceed without modification. ✅ Favorable

📄[Communiqué de presse] – MaaT Pharma annonce le résultat positif de l’analyse intermédiaire de sécurité du DSMB pour l'essai clinique de Phase 2b en cours évaluant MaaT033 pour les patients recevant une allo-GCSH 🩸 Points clés : ✅ Le DSMB a recommandé la poursuite de l'essai

📰 MaaT Pharma in Le Point! We’re proud to be featured in the special issue “Ces projets qui façonnent la santé du futur” (Shaping the future of healthcare), written by Valérie Peiffer and Raphaël Ruffier-Fossoul, highlighting our pioneering work in restoring gut microbiome

📰 More Great Media Coverage for our positive safety update for MaaT033 in Phase 2b trial! We’re proud to see Investir Les Echos cover the DSMB’s favorable interim safety assessment in our ongoing study in allo-HSCT patients. 👉 Read the article here: investir.lesechos.fr/actu-des-valeu…

📰 #Media - We’re proud to be featured for the first time in Het Financieele Dagblad FD Nieuws, a leading Dutch financial daily newspaper, In an article highlighting the thriving life sciences ecosystem in Lyon, the piece includes our recent clinical milestones, our

📄 [Communiqué de Presse] – MaaT Pharma annonce la mise à disposition du Document d’Enregistrement Universel (DEU) 2024 👉 Accéder au document : maatpharma.com/fr/investisseu…

📄 [Press release] – MaaT Pharma Announces the Availability of its 2024 Universal Registration Document (URD) 👉 Access the document: maatpharma.com/investors/#inf…

📢 [#EVENT] - We are proud to share that Bastien Laperrousaz, our Director of Preclinical Development, will be presenting at the American Association for Cancer Research AACR Annual Meeting 2025. He will comment on promising preclinical data for MaaT034, our synthetic microbiome

Live at #EHA2025 - proud to see Prof. Mohty Mohamad Mohty presenting promising data for GvHD patients treated with Xervyteg!

📻𝗜𝗔𝗖𝗛 𝗥𝗮𝗱𝗶𝗼: 𝗢𝗻 𝗔𝗶𝗿 𝗳𝗿𝗼𝗺 #EHA2025 𝘗𝘰𝘰𝘭𝘦𝘥 𝘍𝘦𝘤𝘢𝘭 𝘈𝘭𝘭𝘰𝘨𝘦𝘯𝘪𝘤 𝘔𝘪𝘤𝘳𝘰𝘣𝘪𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘧𝘰𝘳 𝘙𝘦𝘧𝘳𝘢𝘤𝘵𝘰𝘳𝘺 𝘎𝘢𝘴𝘵𝘳𝘰𝘪𝘯𝘵𝘦𝘴𝘵𝘪𝘯𝘢𝘭 𝘈𝘤𝘶𝘵𝘦 𝘎𝘳𝘢𝘧𝘵-𝘷𝘦𝘳𝘴𝘶𝘴-𝘏𝘰𝘴𝘵 𝘋𝘪𝘴𝘦𝘢𝘴𝘦 iach.org/iach-news-podc…